Sign In
Buy BNTX
$90.58
-2.27 (-2.44%)
At Close: Jul 31, 2026
BioNTech: The Market Is Pricing Low Oncology Success
09:46am, Wednesday, 25'th Feb 2026
BioNTech SE is transitioning from a COVID-19 vaccine story to a late-stage oncology platform with a robust $17B cash position. At a $27.6B market cap and ~$11B enterprise value, BNTX's pipeline—incl
BioNTech to Report Fourth Quarter and Full Year 2025 Financial Results and Corporate Update on March 10, 2026
06:45am, Tuesday, 24'th Feb 2026
MAINZ, Germany, February 24, 2026 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will announce its financial results for the fourth quarter and full year 2025 on T
BioNTech sues Moderna for patent infringement over COVID-19 shots
01:25pm, Thursday, 19'th Feb 2026
Biopharmaceutical company BioNTech sued Moderna in Delaware federal court on Thursday, alleging that Moderna's COVID-19 vaccine mNexspike infringes a patent related to BioNTech and Pfizer's competing
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
08:00am, Wednesday, 28'th Jan 2026
Mainz, Germany, January 28, 2026 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that the Supervisory Board has appointed Kylie Jimenez to the Mana
2 Biotech Stocks Set to Rebound in 2026
01:15pm, Tuesday, 27'th Jan 2026
Following recent challenges, these drugmakers could see solid clinical progress in the next 12 to 18 months. Both could launch products with significant sales potential and ride that wave through the
BioNTech (BNTX) Soars 11.8%: Is Further Upside Left in the Stock?
11:30am, Thursday, 22'nd Jan 2026
BioNTech (BNTX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
BioNTech Pivots Back to Oncology at JPM Conference, Teases 15 Phase III Readouts and $17B Cash Plan
04:04am, Wednesday, 14'th Jan 2026
BioNTech (NASDAQ: BNTX) used a presentation and question-and-answer session at the J.P. Morgan Healthcare Conference to highlight its transition back toward oncology, outline a slate of upcoming clini
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
10:45pm, Tuesday, 13'th Jan 2026
BioNTech SE (BNTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
06:45am, Monday, 12'th Jan 2026
Mainz, Germany, January 12, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) will provide a strategic business update and outline the Company's focus areas for 2026, including
University of Pennsylvania, BioNTech, and OUP Launch $50 Million Life Sciences Fund
10:00am, Friday, 09'th Jan 2026
PHILADELPHIA--(BUSINESS WIRE)--The University of Pennsylvania (“Penn”), BioNTech SE (“BioNTech”), and OUP (Osage University Partners) announced the launch of the $50 million Penn-BioNTech Inno
BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
04:45am, Thursday, 18'th Dec 2025
MAINZ, Germany, December 18, 2025 – BioNTech SE (Nasdaq: BNTX, “BioNTech”, or “the Company”) today announced the closing of its acquisition of CureVac N.V. (Nasdaq: CVAC, “CureVac”) and
FDA Weighs Black Box Warning For COVID Vaccines, Experts Push Back
01:51pm, Friday, 12'th Dec 2025
FDA officials are weighing a black box warning for Covid vaccines, a proposal that has drawn strong criticism from outside experts citing lack of evidence.
Moderna Sounds the Alarm: Is China About to Seize the Biotech Crown from the U.S.?
02:03pm, Thursday, 11'th Dec 2025
Investors watching the global biotech race may be sensing a shift after Moderna (MRNA) co-founder and chairman Noubar Afeyan suggested the US could be losing mo
BioNTech: Maintaining "Strong Buy" After Part 1 Success Of Next-Gen Anti-CTLA-4 Gotistobart
05:54pm, Tuesday, 09'th Dec 2025
BioNTech (BNTX) maintains a "Strong Buy" rating, driven by positive phase 3 data for gotistobart in 2nd-line squamous NSCLC patients. BNTX's gotistobart delivered a 63.1% 12-month OS rate versus 30.3%
BioNTech-Bristol Drug Shows Hope For Breast Cancer Patients With Few Options
12:38pm, Tuesday, 09'th Dec 2025
BioNTech and Bristol Myers Squibb share positive data from Phase 2 trial of pumitamig plus chemotherapy for triple-negative breast cancer.
